Navigation Links
Synaptics to Report First Quarter Results on October 23
Date:10/9/2008

SANTA CLARA, Calif., Oct. 9 /PRNewswire-FirstCall/ -- Synaptics(R) Incorporated (Nasdaq: SYNA), a leading developer of human interface solutions for mobile computing, communications, and entertainment devices, announced today that it will report financial results for the first quarter of fiscal 2009 on Thursday, October 23, 2008 after the close of market. The company will host a corresponding conference call for analysts and investors at 2:00 p.m. PT (5:00 p.m. ET) during which management may discuss forward-looking information. Participating on the call will be President and CEO Francis Lee and CFO Russ Knittel.

To participate on the live call, analysts and investors should dial 800-257-1927 at least ten minutes prior to the call. Synaptics will also offer a live and archived webcast of the conference call, accessible from the "Investor Relations" section of the company's Web site (http://www.shareholder.com/synaptics/). A telephonic replay of the conference call will also be available until 11:59 pm PT on Monday, October 27, 2008 by dialing 800-405-2236 and entering the passcode: 11120623#.

About Synaptics Incorporated

Synaptics is a leading developer of human interface solutions for the mobile computing, communications, and entertainment industries. The company creates interface solutions for a variety of devices including notebook PCs, PC peripherals, digital music players, and mobile phones. The TouchPad(TM), Synaptics' flagship product, is integrated into a majority of today's notebook computers. Consumer electronics and computing manufacturers use Synaptics' solutions to enrich the interaction between humans and intelligent devices through improv
'/>"/>

SOURCE Synaptics Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology news :

1. Synaptics SecurePad(TM) Selected as CES Innovations 2008 Design and Engineering Award Honoree
2. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
3. Giant grass offers clues to growing corn in cooler climes, researchers report
4. NTP finalizes report on Bisphenol A
5. Previous claims of siRNA therapeutic effects called into question by report in human gene therapy
6. LSUHSC research reports new method to protect brain cells from diseases like Alzheimers
7. National Research Council report on security at federally managed dams
8. Communication Intelligence Corporation Reports Second Quarter 2008 Financial Results
9. BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008
10. Carbon Disclosure Project, ICLEI partner to help US cities report local climate actions, emissions
11. Baker Institute report proposes strategies to ensure global energy security

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...Chronic obstructive pulmonary disease (COPD), a re...itis or emphysema, is the fourth leading cause of ...D and while researchers have yet to find any real ...ch Institute at The University of Western Ontario ...ques to gain new insight into the disease. , ...
(Date:11/19/2009)...It,s a naturally occurring brain chemical with an ...mouth, it can be abused or used as a date-rape dru...s have determined new routes by which 4-HB is meta...formation," said K. Michael Gibson, professor and ...ical University and a member of the research team....
(Date:11/19/2009)...MADISON This week, scientists are revealing the g...ree cereal crops. Corn, or maize, has one of the m...niversity of Wisconsin-Madison genomicist David Sc...e article in the journal Science . , "The maize...and dead-ends that have troubled would-be sequence...
Breaking Biology News(10 mins):Gaining a better picture of lung disease 2Researchers begin to decipher metabolism of sexual assault drug 2Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3Public Health Faith Leaders Call on DC Council to Renew Funding for Successful Tobacco Prevention Programs 57025 1Public Health Faith Leaders Call on DC Council to Renew Funding for Successful Tobacco Prevention Programs 57025 2Public Health Faith Leaders Call on DC Council to Renew Funding for Successful Tobacco Prevention Programs 57025 3Public Health Faith Leaders Call on DC Council to Renew Funding for Successful Tobacco Prevention Programs 57025 4Enobia Announces Positive Clinical Results With ENB 0040 a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia 4996 1Enobia Announces Positive Clinical Results With ENB 0040 a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia 4996 2Enobia Announces Positive Clinical Results With ENB 0040 a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia 4996 3National Certification for Medical Interpreters Public Call for Final Written Pilot Exam 57018 1National Certification for Medical Interpreters Public Call for Final Written Pilot Exam 57018 2
...d a novel method for attaching small molecules, su...re used to capture large biomolecules. By varying...s, researchers can make the technique applicable t...chemical warfare agents, and environmental polluta...ntify synthetic biomolecules that recognize neurot...
...ity of Pennsylvania and Johns Hopkins University h...ommonly activated proteins in cancer is so dangero... Myc protein can stop the production of at least 1...p control which genes are turned on and off., Fur...ressed miRNAs ,into Myc-containing cancer cells su...
...th the designation of Threatened by the Committee ...SEWIC). COSEWIC is the scientific body that advise...at risk. , Since 1967, the number of chimney swi...y swifts are sooty-coloured, swallow-like birds th...rick-lined chimneys. From late April to early Octo...
Other Biology News:Biocapture surfaces produced for study of brain chemistry 2University of Pennsylvania researchers zero in on the tiniest members in the war on cancer 2
(Date:11/20/2009)...OLM, November 20 Karolinska Develo...ent Fund (EIF) has entered into a,co-investment ag...ill be,managed by Karolinska Development and used ...e pharmaceutical and medical technology companies....nvestment fund. The agreement,represents EIF,s lar...
(Date:11/19/2009).... 19 Danish Prince Joachim inaugur...l plant in Kalundborg, Denmark, on Wednesday, Nove...and largest 2nd generation ethanol demonstration b...sed in the plant,s innovative process for converti... was the first to market with commercial enzymes f...
(Date:11/19/2009)... Nov. 19 Spherix Incorpo...ogy for diabetes therapy, and a provider of techni...pplement, biotechnology and pharmaceutical compani...l Meeting of Shareholders. ,, At the meeting, s... ) elected the following members to the Board of D...
(Date:11/19/2009)... World,s Top Gene Synthesis Companies Form Interna...ate Best Practices in Risk Reduction ,Five Membe... Synthesis Capacity , (PR...s leading gene synthesis companies today announced... protocol to promote biosecurity in the gene synth...
Breaking Biology Technology:Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
...icals, Inc.,a privately held biopharmaceutical com...ounced new data on its lead product, varespladib (...ual Conference in New Orleans,Louisiana. Anthera h...r the,treatment of coronary heart disease. At the ...ased new data from the Phase II PLASMA-2 study, wh...
...cut,s highest honor for technological achievement,...to Yale Professor Tso-Ping (T.P.) Ma for his pio...ut Medal of Technology is awarded by the Board of ...t Academy of Science and Engineering . It is given...Science and is designed to laud individuals "for s...
...rowth of 12.9 percent,- Full year revenue growth o... and improving profitability reflects success of s...ual financial guidance for fiscal year 2009, BATE...E: HRC ), announced unaudited financial results f...008 -- the second quarter of operations,following ...
Other Biology Technology:Anthera's Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease 2Yale professor T.P. Ma awarded the Connecticut Medal of Technology 2Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 2Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 3Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 4Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 5Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 6Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 7Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 8Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 9Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 10Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 11Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 12Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 13Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 14Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 15Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 16Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 17Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 18Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 19
Rabbit Anti-Human Naked1 Polyclonal Antibody, Unconjugated from Cell Signaling Technology
Rabbit Anti-NF-kB p65, phospho (Ser345) Antibody, Unconjugated from Spring Bioscience
Anti-NSP-C (Neuroendocrine-Specific-Protein) Monoclonal Antibody, Unconjugated, Clone RNL-4 from CHEMICON
Rabbit Anti-Human ADAMTS-4, disintegrin-like domain Antibody, Unconjugated from CHEMICON
Biology Products: